QUREHealthcare · BiotechnologyThe 12 Wall Street analysts covering UniQure NV hold a median 12-month price target of $69 — +206.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores UniQure NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (89): The business earns solid, repeatable profits on what it owns.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on QURE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +206.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | Barclays | Downgrade | Equal-Weight | $60 → $28 |
| 2 Oct 2026 | RBC Capital | Maintains | Outperform | $65 → $48 |
| 30 Sept 2026 | Goldman Sachs | Maintains | Neutral | $46 → $31 |
| 2 Sept 2026 | William Blair | Reinstates | Outperform | — |
| 30 July 2026 | Barclays | Maintains | Overweight | — |
| 30 July 2026 | Barclays | Maintains | Overweight | $65 → $60 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $60 → $75 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 30 July 2026 | Wolfe Research | Upgrade | Outperform | — |
| 30 July 2026 | Wolfe Research | Upgrade | Outperform | $65 |
| 29 June 2026 | HC Wainwright & Co. | Maintains | Buy | $50 → $80 |
| 29 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 June 2026 | Mizuho | Maintains | Outperform | $35 → $68 |
| 25 June 2026 | Mizuho | Maintains | Outperform | — |
| 18 June 2026 | Barclays | Upgrade | Overweight | — |
| 18 June 2026 | Goldman Sachs | Maintains | Neutral | — |
| 18 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 18 June 2026 | RBC Capital | Maintains | Outperform | — |
| 6 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Apr 2026 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QURE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, UniQure NV returned −62.4% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 4% of US stocks
Cheaper than 20% of US stocks
Cheaper than 82% of US stocks
Higher than 55% of US stocks
Higher than 49% of US stocks
Higher than 98% of US stocks
Higher than 6% of US stocks
Higher than 99% of US stocks
Higher than 9% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
UniQure NV has a market value of $1.6B and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter grew 11.0% year on year.
Net income over the same four quarters: −$252.2M, a −1350.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$161.5M.
Trailing P/E: −6.5×; forward P/E: −7.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
UniQure NV employs 221 people — $84K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own UniQure NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cedar Grove Capital said it closed its long position in uniQure during the quarter, as reported in its Q3 2026 portfolio update.
Why it matters — The update indicates Cedar Grove Capital no longer held a long position in QURE at quarter-end.
Kirby McInerney LLP said it is investigating possible federal securities law violations or other unlawful business practices by uniQure and/or its senior management. The notice references a 37.3% share drop and the company’s September 29, 2026 release of 48-month data from ongoing Phase I/II AMT-130 studies.
Why it matters — QURE investors may follow the investigation and the cited AMT-130 data release as developments involving the company.
Schaeffers Research published a list of 10 stocks with massive short squeeze potential, framed against a backdrop of rising bond yields, oil prices, and inflation rhetoric heading into Q4, with UniQure among the names examined as short sellers reposition.
Why it matters — A QURE watcher would care because the stock's inclusion on a short-squeeze watchlist signals notable short interest and the potential for outsized price moves based on market sentiment and positioning.
Kirby McInerney LLP announced it is investigating potential claims against uniQure N.V. over whether the company and/or senior management may have violated federal securities laws or engaged in other unlawful business practices. The firm is inviting investors who acquired uniQure securities to contact it about their rights.
Why it matters — A securities investigation against the company raises legal and regulatory risk that could affect QURE shareholders.
uniQure's Huntington's disease gene therapy showed sustained functional benefits at 36 months, but newly reported 48-month data were mixed, injecting uncertainty into the program. The company's stock fell on the additional data release.
Why it matters — The mixed longer-term data add uncertainty around the durability of uniQure's key Huntington's disease therapy, a central driver of the company's valuation.
The 12 Wall Street analysts covering UniQure NV have a median 12-month price target of $69, with estimates ranging from $28 to $91. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering UniQure NV, 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks UniQure NV 50 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, UniQure NV ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (89 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +206.9% from the last close, and Ticker Nerd's factor model ranks UniQure NV 50 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering UniQure NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QURE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $91 over the next 12 months.
UniQure NV returned -62.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases.
The most recent item we track (Seeking Alpha, 7 Oct 2026): "Cedar Grove Capital Q3 2026 Portfolio Update". Cedar Grove Capital said it closed its long position in uniQure during the quarter, as reported in its Q3 2026 portfolio update.
uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.
CEO Mr. Matthew Craig Kapusta CPA · 221 employees · Netherlands · https://www.uniqure.com
